Non-immunogenic Staphylokinase in Reperfusion Therapy of Ischemic Stroke in Routine Clinical Practice

Recruiting now

Conditions studied: Acute Stroke

In brief

The study will collect data from aged 18 to 85 years with a diagnosis of acute stroke, who received thrombolytic treatment with a new agent, nonimmunogenic staphylokinase. Outcomes will be checked for safety and compared to the results of treatment with the other thrombolytic drug, alteplase.

Key facts

Study ID

NCT05697575

Run by

National Society for Neurosonology and Cerebral Circulation

People needed

336

Starts

2023-02-01

Expected to finish

2030-05-10

Last updated by the study team

2026-04-13

Who can join

Age: 18 and older, up to 85. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Age 18-85 ;
• Diagnosis of acute ischemic stroke eligible for thrombolytic therapy;
• Thrombolytic therapy with the drug "non-immunogenic staphylokinase" is planned or has already been performed.

You may not qualify if…

• Individual intolerance or known hypersensitivity to a recombinant protein containing the amino acid sequence of staphylokinase;
• The presence of a contraindication to thrombolytic therapy of ischemic stroke;
• Pregnancy or lactation.

Where it is running

• St. Petersburg Research Institute of Emergency Medicine named after I.I. Janelidze — Saint Petersburg, Russia (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.